The real-world challenge pharma can’t ignore: Sustained engagement
May 19, 2026 | Healthcare communication, Making Health Whole, medcomms
Breakthrough therapies do not fail because the science stops working. They fail when healthcare is not designed for the physical, emotional and mental realities shaping how people engage with treatment in everyday life.
Breakthrough therapies do not fail in the real world because the science stops working. They fail because life gets in the way.
Across healthcare, many pharmaceutical and biotech teams are doing everything right clinically. Strong data. Clear guidelines. Innovative products. And yet engagement still quietly breaks down.
Treatment is delayed. Monitoring is missed. Motivation declines. People disengage before they fully benefit.
These are often described as adherence challenges. But the issue is rarely efficacy alone.
It reflects something broader: whether healthcare has been designed for the realities shaping how people engage with treatment in everyday life.
How people engage with their health is influenced by far more than clinical information. It is shaped by the full human context behind every health decision and behaviour – the physical demands of treatment; the emotional impact of uncertainty and identity change; and the mental load of understanding, deciding and maintaining routine.
This is the challenge Making Health Whole™ was created to address.
Where engagement becomes fragile
Across chronic conditions, engagement rarely collapses dramatically. It erodes over time.
At diagnosis, people may feel overwhelmed by information and uncertainty. During treatment initiation, side effects, complexity and fear can create hesitation. Later, motivation often declines when benefits are preventative, delayed or difficult to feel.
Alongside this, people are navigating work, relationships, finances, caregiving responsibilities and the emotional pressure of managing a condition over time.
This is where engagement becomes fragile. Not because people do not value treatment, but because healthcare systems are often designed around the condition rather than the person living with it.
This has significant commercial implications.
When engagement breaks down:
- persistence declines
- real-world outcomes weaken
- health economic value becomes harder to demonstrate
- avoidable system costs increase
- brand performance suffers over time
For commercial, market access and procurement teams, this is no longer a peripheral issue. Sustained engagement directly influences healthcare efficiency, pathway continuity and the long-term impact of innovation.
From information delivery to engagement by design
Many engagement strategies still focus on delivering more information. But information alone does not change behaviour.
Making Health Whole starts from a different assumption: engagement does not happen by default. It has to be designed for.
That means understanding where engagement becomes difficult, what creates friction across the treatment journey, and why the next step can begin to feel overwhelming.
It also means designing for real life: how people think, feel and act under pressure. Considering not only what is clinically required, but what feels manageable, what feels possible.
In practice, this means reducing cognitive overload; strengthening confidence and autonomy; simplifying routines and next steps; and addressing emotional barriers before disengagement takes hold.
Engagement as a differentiator
When people feel supported in the reality of their lives, they are more likely to take control, stay on track and achieve optimal outcomes.
For pharmaceutical and biotech organisations, this creates measurable impact:
- stronger treatment persistence
- reduced avoidable drop-off
- improved real-world performance
- lower downstream system burden
- stronger relationships with patients, HCPs and payers
Clinical claims are increasingly comparable. The experience of engaging with treatment is not.
Brands that design for sustained engagement create differentiation that extends beyond efficacy alone. They support people not only to start treatment, but to continue engaging with it over time.
Turning insight into action
One of the fastest ways to begin is through a structured whole-health audit of the existing ecosystem. Identifying where engagement becomes fragile across the existing experience and where emotional, mental and practical barriers increase the risk of drop-off over time.
From there, support can be redesigned around the whole person, not just the treatment pathway.
This content was provided by Mednet